LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

Kodu・Aktsiate loetelu・Denali Therapeutics Inc

Denali Therapeutics Inc

Suletud

SektorTervishoid

18.12 -1.47

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

17.73

Max

18.39

Põhinäitajad
By Trading Economics
Sissetulek	102K -128M
Aktsiakasum	-0.69
Töötajad	507
EBITDA	-9.8M -135M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+95.16% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-42M 2.9B
Eelmine avamishind	19.59
Eelmine sulgemishind	18.12

Uudiste sentiment

By Acuity

50%

174 / 345 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

13.355 / 16.44 Toetus ja vastupanu

Denali Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. mai 2026, 20:36 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19. mai 2026, 23:47 UTC

Market Talk

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19. mai 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19. mai 2026, 23:28 UTC

Market Talk

Tulu

Global Forex and Fixed Income Roundup: Market Talk

19. mai 2026, 23:28 UTC

Market Talk

Tulu

F&P Healthcare's Outlook Key for Investors -- Market Talk

19. mai 2026, 23:10 UTC

Market Talk

Global Equities Roundup: Market Talk

19. mai 2026, 23:10 UTC

Market Talk

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19. mai 2026, 22:02 UTC

Tulu

ZTO Express (Cayman): Di Xu to Resign From Board

19. mai 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19. mai 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19. mai 2026, 22:00 UTC

Tulu

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19. mai 2026, 21:37 UTC

Tulu

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19. mai 2026, 21:31 UTC

Omandamised, ülevõtmised, äriostud

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19. mai 2026, 21:01 UTC

Tulu

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19. mai 2026, 20:58 UTC

Tulu

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19. mai 2026, 20:46 UTC

Kuumad aktsiad

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19. mai 2026, 20:43 UTC

Market Talk

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19. mai 2026, 20:34 UTC

Tulu

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19. mai 2026, 20:32 UTC

Tulu

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19. mai 2026, 20:32 UTC

Tulu

James Hardie Industries 4Q EPS 5c >JHX

19. mai 2026, 20:32 UTC

Tulu

James Hardie Industries 4Q Sales $1.4B >JHX

19. mai 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices to Buy Empower Semiconductor for $1.5B

19. mai 2026, 20:18 UTC

Market Talk

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19. mai 2026, 20:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19. mai 2026, 20:13 UTC

Market Talk

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19. mai 2026, 20:03 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19. mai 2026, 20:03 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19. mai 2026, 20:02 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19. mai 2026, 20:02 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19. mai 2026, 19:23 UTC

Market Talk

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Denali Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

95.16% tõus

12 kuu keskmine prognoos

Keskmine 35.91 USD 95.16%

Kõrge 42 USD

Madal 23 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Denali Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Denali Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

13.355 / 16.44Toetus ja vastupanu

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

174 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.